Carol Viele, RN, MS, OCN, CNS is a licensed clinical nurse specialist and an associate clinical professor at the University of California San Francisco School of Nursing. She has nearly 25 years of experience in bone marrow transplantation and oncology supportive care. Ms. Viele spoke with Oncology Data Advisor about why sinusoidal obstruction syndrome (SOS) is still a major concern in cancer care, progress in identifying at-risk patients, and the role of oncology nurses in prophylaxis and treatment.

Discussion Notes: On why SOS is still a major concern in oncology care [1:11] On recent progress in SOS risk stratification [5:00] On steps to prevent SOS [7:20] On barriers still facing optimal SOS management [8:36] On her most challenging case of SOS [11:50] On counseling patients at risk for SOS [16:25] On the role of oncology nurses in prophylaxis and treatment of SOS [17:55]

Louis F. Diehl, MD is a professor of medicine at Duke University School of Medicine with a long-standing interest and involvement in the staging and treatment of hematologic malignancies. He recently served as chairperson of the 2016 Asheville Hematologic Malignancies Symposium where Oncology Data Advisor spoke with him about the evolving standards of care in hematologic malignancies, the challenges of incorporating biosimilars in contemporary practice, and advances specific to follicular lymphoma treatment.

Discussion Notes: On the evolving standards of care in hematologic malignancies [1:38] On the challenges of incorporating biosimilars in contemporary practice [3:25] On new advances in follicular lymphoma treatment [4:16]

Anjali Advani, MD is an associate professor at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University. Her main clinical interests include myelodysplasia and acute leukemias, with a focus on molecular targeted therapies and novel treatment strategies for acute myeloid leukemia and acute lymphoblastic leukemia (ALL). She spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about new and upcoming advances in frontline ALL treatment, the challenge of managing relapsed/refractory ALL, and when to select a pediatric-inspired regimen or bone marrow transplant.

Discussion Notes: On new advances in frontline treatment of ALL [0:58] On the challenge of managing relapsed/refractory ALL [1:33] On who should receive pediatric-inspired regimens [2:41] On identifying patients eligible for bone marrow transplant [4:00]

Jeffrey Zonder, MD is a professor of oncology at the Karmonos Cancer Institute in Detroit, Michigan. He has won teaching awards at Wayne State University in 2005 and 2007, is a member of the SWOG Barlogie-Salmon Myeloma Committee, serves as a medical advisor for Amyloidosis Support Groups, Inc, and runs the blog, Amyloid Planet. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about recently approved and emerging therapies in multiple myeloma, the greatest challenges still facing myeloma management, and how he uses social media to discuss new and exciting research.

Discussion Notes: On establishing deeper responses with new and standard techniques [0:56] On the most exciting data from recent clinical trials and emerging therapies in multiple myeloma [1:52] On the greatest challenges still facing myeloma management [3:38] On using social media for an online journal club [4:42] On the future of myeloma therapies and the need for clinical trials [5:39]

Jeffrey Zonder, MD is a professor of oncology at the Karmonos Cancer Institute in Detroit, Michigan. He has won teaching awards at Wayne State University in 2005 and 2007, is a member of the SWOG Barlogie-Salmon Myeloma Committee, serves as a medical advisor for Amyloidosis Support Groups, Inc, and runs the blog, Amyloid Planet. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about recently approved and emerging therapies in multiple myeloma, the greatest challenges still facing myeloma management, and how he uses social media to discuss new and exciting research.

Discussion Notes: On establishing deeper responses with new and standard techniques [0:56] On the most exciting data from recent clinical trials and emerging therapies in multiple myeloma [1:52] On the greatest challenges still facing myeloma management [3:38] On using social media for an online journal club [4:42] On the future of myeloma therapies and the need for clinical trials [5:39]

John Leonard, MD is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medical College in New York City. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about optimizing therapeutic approaches for mantle cell lymphoma in the context of limited randomized trial data and tips for counseling patients about their disease and its treatment.

Discussion Notes: On treatment planning in the context of limited randomized trial data [1:15] On the unique challenges of treating MCL compared with other lymphomas [2:43] On counseling patients about their treatment experience [4:13]

John Leonard, MD is the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medical College in New York City. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about optimizing therapeutic approaches for mantle cell lymphoma in the context of limited randomized trial data and tips for counseling patients about their disease and its treatment.

Discussion Notes: On treatment planning in the context of limited randomized trial data [1:15] On the unique challenges of treating MCL compared with other lymphomas [2:43] On counseling patients about their treatment experience [4:13]

Michael Mauro, MD is the leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center in New York City. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about the implications of generic cancer drugs for clinical decision making, managing highly resistant patients, and expected data from the 2016 ASCO Annual Meeting.

Discussion Notes: On concerns over the use generic imatinib [1:38] On greatest challenges in treatment planning [3:02] On what we might see at the 2016 ASCO Annual Meeting [4:16]

Michael Mauro, MD is the leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center in New York City. He spoke with Oncology Data Advisor at the 2016 Asheville Hematologic Malignancies Symposium about the implications of generic cancer drugs for clinical decision making, managing highly resistant patients, and expected data from the 2016 ASCO Annual Meeting.

Discussion Notes: On concerns over the use generic imatinib [1:38] On greatest challenges in treatment planning [3:02] On what we might see at the 2016 ASCO Annual Meeting [4:16]

Steven Horwitz, MD is an associate professor of medicine at Weill Cornell Medical College and a medical oncologist at Memorial Sloan Kettering Cancer Center in New York City. Oncology Data Advisor spoke with Dr. Horwitz at the 2016 Asheville Hematologic Malignancies Symposium about current challenges and new opportunities in the treatment of patients with T-cell lymphoma.

Discussion Notes: Caveats for community oncologists [0:30] On the question Dr. Horwitz most often hears from his patients [2:11] On the greatest challenges facing T-cell lymphoma treatment [3:38] On the most promising recent advances in T-cell lymphoma [4:08]